employee
Russian Federation
graduate student from 01.01.2024 to 01.01.2026
Krasnodar, Krasnodar, Russian Federation
VAK Russia 4.1.2
VAK Russia 4.1.3
VAK Russia 4.1.4
VAK Russia 4.1.5
VAK Russia 4.2.1
VAK Russia 4.2.2
VAK Russia 4.2.3
VAK Russia 4.2.4
VAK Russia 4.2.5
VAK Russia 4.3.3
VAK Russia 4.3.5
UDC 619
UDC 616
UDC 616.65-002-007.61
UDC 615.03
The objective of the study is to analyze and evaluate the current status of benign prostatic hyperplasia (BPH) in dogs, including epidemiology, etiopathogenesis, the use of instrumental and laboratory diagnostic methods, treatment strategies, and the use of pharmacotherapeutic agents, with an emphasis on promising pharmaceutical developments. The review utilizes literature published between 2015 and 2025 on BPH in dogs. Diagnosis of BPH in dogs relies on a combination of clinical manifestations, physical examination, and instrumental examination methods, with ultrasound and radiography being the dominant methods. A serum test for determining the level of one potential biomarker for BPH in dogs, canine prostate-specific esterase (PSE), has demonstrated promise in laboratory testing. Recent data on the pathogenesis of BPH in dogs highlight its multi-layered nature (dominated by hormonal changes), requiring a comprehensive approach to BPH treatment and the development of targeted drugs. Castration is considered the primary treatment for BPH in dogs; however, it is not always appropriate. Pharmacotherapy for the disease includes antiandrogens (osaterone acetate), 5α-reductase inhibitors (finasteride, dutasteride), α1-adrenergic blockers (terazosin, tamsulosin, etc.), gonadotropin-releasing hormone (GnRH) agonists (deslorelin), and combination therapies. Prospects for new drugs focus on targeted molecular mechanisms, including selective androgen receptor modulators (SMAPs) (ligandrol), aromatase inhibitors (letrozole), and phytotherapeutic agents (saw palmetto, African pygeum, stinging nettle, etc.). Of clear interest is the design of targeted drugs based on various combinations of promising pharmacological agents, both with each other and in combination with the most effective and already used agents for the treatment of BPH in dogs (finasteride, osaterone, deslorelin), in innovative dosage forms with improved pharmacokinetic and biopharmaceutical properties.
dogs, prostate gland, benign prostatic hyperplasia, epidemiology, prevalence, diagnosis, etiology, pathogenesis, treatment, targeted drugs, pharmacotherapy
1. Chernaya KO, Pigareva GP. Diagnostika i rasprostranenie patologii predstatel'noy zhelezy u sobak v usloviyakh goroda Voronezha. Ippologiya i veterinariya. 2023;1:31-37. (In Russ.). DOI: 10.52419/ 2225-1537/2023.1.31-37.
2. Stoilov PG, Lakovnikov EA, Nikolaeva OA. Ekhograficheskaya i tsitologicheskaya diagnostika zabolevaniy predstatel'noy zhelezy u sobak. Mezhdunarodnyy vestnik veterinarii. 2010;3:31-34. (In Russ.).
3. Saldivia PMM, Seguel BF. Anatomy of the prostate gland and seminal colliculi of the canine (Canis lupus familiaris). Anatomy Physiology Biochemistry International Journal. 2019;5(4):555670.
4. Yaroslavskaya AM. Prichiny vozniknoveniya zabolevaniy predstatelnoy zhelezy u sobak. In: Aktualnye voprosy nezaraznoy patologii zhivotnykh. Ulyanovsk: Ulyanovsk SAU named after PA Stolypin; 2017. P. 292–294. (In Russ.).
5. Slesarenko NA, Kolyadina NA, Golubtsova DA. Morfologicheskie i morfometricheskie pokazateli predstatelnoy zhelezy u sobak. Veterinariya i kormlenie. 2022;2:50-52. DOI:https://doi.org/10.30917/ATT-VK-1814-9588-2022-2-14. (In Russ.).
6. Leav I, Schelling KH, Adams JY, et al. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma. Prostate. 2001;48(3):210-224.
7. Pigareva GP, Chernaya KO. Zabolevaniya predstatelynoy zhelezy u sobak. Veterinarno-sanitarnye aspekty kachestva i bezopasnosti selskokhozyaystvennoy produktsii. Voronezh: Voronezh State Agrarian University; 2021. P. 294–299. (In Russ.). EDN: https://elibrary.ru/SFSDIX.
8. Ruel Y, Barthez PY, Mailles A, et al. Ultrasonographic evaluation of the prostate in healthy intact dogs. Veterinary Radiology & Ultrasound. 1998;39(3):212-216.
9. Cazzuli G, Damian JP, Molina E, et al. Post-castration prostatic involution: a morphometric and endocrine study of healthy canines and those with benign prostatic hyperplasia. Reprod Domest Anim. 2022;57(2):157-164. DOI:https://doi.org/10.1111/rda.14088.
10. Berry SJ, Strandberg JD, Saunders WJ, et al. Development of canine benign prostatic hyperplasia with age. Prostate. 1986;9(4):363-373.
11. Vorobievskaya SV, Statsenko MI, Kovaleva VYu, et al. Sovershenstvovanie diagnostiki i lecheniya zabolevaniy predstatel'noy zhelezy u sobak [Improvement of diagnosis and treatment of prostate diseases in dogs]. Aktual'nye voprosy sel'skokhozyaystvennoy biologii. 2021;4:17-30. (In Russ.).
12. Mahapokai W, van Sluijs FJ, Schalken JA. Models for studying benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases. 2000;3(1):28-33.
13. Shidaifat F. Age-dependent expression of 5alpha-reductase and androgen receptors mRNA by the canine prostate. Physiological Research. 2009;58(1):155-158.
14. Wilson JD. The critical role of androgens in prostate development. Endocrinology and Metabolism Clinics of North America. 2011;40(3):577-590. DOI:https://doi.org/10.1016/j.ecl.2011.05.001.
15. Kim BH, Kim CI, Chang HS, et al. Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer? Korean Journal of Urology. 2001;42:359-363.
16. Flores RB, Angrimani DSR, Rui BR, et al. The influence of benign prostatic hyperplasia on sperm morphological features and sperm DNA integrity in dogs. Reproduction in Domestic Animals. 2016;51(2):269-275. DOI:https://doi.org/10.1111/rda.12677.
17. Lotti F, Tamburrino L, Marchiani S, et al. DNA fragmentation in two cytometric sperm populations: relationship with clinical and ultrasound characteristics of the male genital tract. Asian Journal of Andrology. 2016;18(3):435-441. DOI:https://doi.org/10.4103/1008-682X.178483.
18. Gunko MV, Chekrysheva VV. Primenenie fitoterapii pri lechenii vospalitel'nykh zabolevaniy u zhivotnykh. Veterinariya Severnogo Kavkaza. 2022;3:53-58. (In Russ.).
19. Voitenko LG, Lapina TI, Golovan IA, et al. Vosstanovlenie reproduktivnoy funktsii korov putem likvidatsii simptomaticheskogo besplodiya. Veterinarnaya patologiya. 2014;(3-4):24-31. (In Russ.).
20. Carson CC 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(4):2-7. DOI:https://doi.org/10.1016/S0090-4295(03)00045-1.
21. Walsh PC, Wilson JD. The induction of prostatic hypertrophy in the dog with androstanediol. Journal of Clinical Investigation. 1976;57(4):1093-1097. DOI:https://doi.org/10.1172/JCI108353.
22. DeKlerk DP, Coffey DS, Ewing LL, et al. Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. Journal of Clinical Investigation. 1979;64(3):842-849. DOI:https://doi.org/10.1172/JCI109532.
23. Wasim S, Lee SY, Kim J. Complexities of Prostate Cancer. Int J Mol Sci. 2022;2(22):14257. DOI:https://doi.org/10.3390/ijms232214257.
24. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annual Review of Pharmacology and Toxicology. 1996;36:203-232. DOI:https://doi.org/10.1146/annurev.pa.36.040196.001223.
25. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. European Urology. 1999;36(1):1-13. DOI:https://doi.org/10.1159/000019919.
26. Mordecai A, Liptak JM, Hofstede T, et al. Prostatic abscess in a neutered cat. Journal of the American Animal Hospital Association. 2008;44(2):90-94. DOI:https://doi.org/10.5326/0440090.
27. Pointer E, Murray L. Chronic prostatitis, cystitis, pyelonephritis, and balanoposthitis in a cat. Journal of the American Animal Hospital Association. 2011;47(4):258-261. DOI:https://doi.org/10.5326/JAAHA-MS-5627.
28. Stans J. Clinical aspects of feline prostate cancer: a literature review. Journal of the Hellenic Veterinary Medical Society. 2021;72(3):2803-2808.
29. Zambelli D, Cunto M, Raccagni R, et al. Successful surgical treatment of a prostatic biphasic tumor (sarcomatoid carcinoma) in a cat. Journal of Feline Medicine and Surgery. 2010;12(3):161-165. DOI:https://doi.org/10.1016/j.jfms.2009.07.016.
30. Tursi M, Costa T, Valenza F, et al. Adenocarcinoma of the disseminated prostate in a cat. Journal of Feline Medicine and Surgery. 2008;10(6):600-602. DOI:https://doi.org/10.1016/j.jfms.2008.02.008.
31. LeRoy BE, Lech ME. Prostatic carcinoma causing urethral obstruction and obstipation in a cat. Journal of Feline Medicine and Surgery. 2004;6(6):397-400. DOI:https://doi.org/10.1016/j.jfms.2004.4.005.
32. Hubbard BS, Vulgamott JC, Liska WD. Prostatic adenocarcinoma in a cat. Journal of the American Veterinary Medical Association. 1990;197(11):1493-1494.
33. Caney SM, Holt PE, Day MJ, et al. Prostatic carcinoma in two cats. Journal of Small Animal Practice. 1998;39(3):140-143. DOI:https://doi.org/10.1111/j.1748-5827.1998.tb03619.x.
34. Kamiya S, Yoshimura H, Okada K, et al. Polyglucosan bodies in the prostatic stromal smooth muscles of aged dogs. Histology and Histopathology. 2017;32(5):499-502. DOI:https://doi.org/10.14670/HH-11-818.
35. Aquilina JW, McKinney L, Pacelli A, et al. High grade prostatic intraepithelial neoplasia in military working dogs with and without prostate cancer. Prostate. 1998;36(3):189-193. DOI:https://doi.org/10.1002/(SICI)1097-0045(19980801)36:3<189::AID-PROS7>3.0.CO;2-C.
36. Waters DJ, Hayden DW, Bell FW, et al. Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer. Prostate. 1997;30(2):92-97. DOI:https://doi.org/10.1002/(SICI)1097-0045(19970201)30:2<92::AID-PROS4>3.0.CO;2-M.
37. Smith J. Canine prostatic disease: a review of anatomy, pathology, diagnosis, and treatment. Theriogenology. 2008;70(3):375-383. DOI:https://doi.org/10.1016/j.theriogenology.2008.04.039.
38. Bell FW, Klausner JS, Hayden DW, et al. Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970–1987). Journal of the American Veterinary Medical Association. 1991;199(11):1623-1630.
39. Leroy BE, Northrup N. Prostate cancer in dogs: comparative and clinical aspects. Veterinary Journal. 2009;180(2):149-162. DOI:https://doi.org/10.1016/j.tvjl.2008.05.011.
40. Sorenmo KU, Goldschmidt MH, Shofer FS, et al. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Veterinary and Comparative Oncology. 2004;2(1):13-23. DOI:https://doi.org/10.1111/j.1476-5810.2004.00039.x.
41. Ravicini S, Baines SJ, Taylor A, et al. Outcome and prognostic factors in medically treated canine prostatic carcinomas: a multi-institutional study. Veterinary and Comparative Oncology. 2018;16(4):450-458. DOI:https://doi.org/10.1111/vco.12397.
42. Goldsmid SE, Bellenger CR. Urinary incontinence after prostatectomy in dogs. Veterinary Surgery. 1991;20(4):253-256. DOI:https://doi.org/10.1111/j.1532-950X.1991.tb00342.x.
43. Bacon N, Souza CHM, Franz S. Total cysto-prostatectomy: technique description and results in 2 dogs. Canadian Veterinary Journal. 2016;57(2):141-146.
44. Stone EA, Withrow SJ, Page RL, et al. Ureterocolonic anastomosis in ten dogs with transitional cell carcinoma. Veterinary Surgery. 1988;17(3):147-153. DOI:https://doi.org/10.1111/j.1532-950X.1988.tb00290.x.
45. Saeki K, Fujita A, Fujita N, et al. Total cystectomy and subsequent urinary diversion to the prepuce or vagina in dogs with transitional cell carcinoma of the trigone area: a report of 10 cases (2005–2011). Canadian Veterinary Journal. 2015;56(1):73-80.
46. Liptak JM, Brutscher SP, Monnet E, et al. Transurethral resection in the management of urethral and prostatic neoplasia in 6 dogs. Veterinary Surgery. 2004;33(5):505-516. DOI:https://doi.org/10.1111/j.1532-950X.2004.04067.x.
47. Weisse C, Berent A, Todd K, et al. Evaluation of palliative stenting for management of malignant urethral obstructions in dogs. Journal of the American Veterinary Medical Association. 2006;229(2):226-234. DOI:https://doi.org/10.2460/javma.229.2.226.
48. L’Eplattenier HF, Klem B, Teske E, et al. Preliminary results of intraoperative photodynamic therapy with 5-aminolevulinic acid in dogs with prostate carcinoma. Veterinary Journal. 2008;178(2):202-207. DOI:https://doi.org/10.1016/j.tvjl.2007.10.003.
49. Kim SH, Yu A, Jung JH, et al. Incidence and risk factors of 30-days early and 90-day late morbidity and mortality of radical cystectomy during a 13-year follow-up: a comparative propensity-score matched analysis of complications between neobladder and ileal conduit. Japanese Journal of Clinical Oncology. 2014;44(8):677-685. DOI:https://doi.org/10.1093/jjco/hyu063.
50. Ahyai SA, Lehrich K, Kuntz RM. Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. European Urology. 2007;52(5):1456-1463. DOI:https://doi.org/10.1016/j.eururo.2007.04.053.
51. Tan A, Liao C, Mo Z, et al. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. British Journal of Surgery. 2007;94(10):1201-1208. DOI:https://doi.org/10.1002/bjs.5916.
52. Kravchenko YuV, Sampiev AM, Abramov AA. Rasprostranennost dobrokachestvennoy giperplazii predstatelynoy zhelezy sredi sobak v Krasnodare. Innovatsionnye nauchnye issledovaniya. 2025;9-1:12-18. DOI:https://doi.org/10.5281/zenodo.18070220. (In Russ.).
53. Kravchenko YuV, Sampiev AM, Abramov AA. Bezopasnost novogo kombinirovannogo preparata dlya lecheniya i profilaktiki dobrokachestvennoy giperplazii predstatelynoy zhelezy u sobak v ramkakh ostrogo toksikologicheskogo eksperimenta. Sbornik nauchnykh trudov Krasnodarskogo nauchnogo tsentra po zootekhnii i veterinarii. 2025;14(1):288-291. DOI:https://doi.org/10.48612/sbornik-2025-1-68. (In Russ.).
54. Colleluori G, Chen R, Turin CG, et al. Aromatase inhibitors plus weight loss improves the hormonal profile of obese hypogonadal men without causing major side effects. Frontiers in Endocrinology. 2020;11:277. DOI:https://doi.org/10.3389/fendo.2020.00277.
55. Niżański W, Ochota M, Fontaine C, et al. Comparison of clinical effectiveness of deslorelin acetate and osaterone acetate in dogs with benign prostatic hyperplasia. Animals. 2020;10(10):1936. DOI:https://doi.org/10.3390/ani10101936.
56. Esin B, Kaya C, Esin Ç. Doppler ultrasonography in the diagnosis of dogs with benign prostatic hyperplasia and investigation of the efficacy of finasteride in treatment. Veterinary Medicine and Science. 2025;11(3):e70337. DOI:https://doi.org/10.1002/vms3.70337.
57. Dearakhshandeh N, Mogheiseh A, Nazifi S, et al. Treatment of experimentally induced benign prostatic hyperplasia with tadalafil and castration in dogs. Theriogenology. 2020;142:236-245. DOI:https://doi.org/10.1016/j.theriogenology.2019.10.040.
58. Schrank M, Romagnoli S. Prostatic neoplasia in the intact and castrated dog: how dangerous is castration? Animals. 2020;10(1):85. DOI:https://doi.org/10.3390/ani10010085.
59. Domosławska-Wyderska A, Zduńczyk S, Rafalska A. Negative impact of benign prostatic hyperplasia on fertility in dogs: a mini-review. Frontiers in Veterinary Science. 2025;12:1582705. DOI:https://doi.org/10.3389/fvets.2025.1582705.
60. Socha P, Zduńczyk S, Tobolski D, et al. The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia. Pol J Vet Sci. 2018;21(4):559-566. DOI:https://doi.org/10.24425/pjvs.2018.125601.
61. Ferré-Dolcet L, Frigotto L, Contiero B, et al. Prostatic fluid composition and semen quality in dogs with benign prostatic hyperplasia undergoing treatment with osaterone acetate. Reprod Domest Anim. 2022;57(1):72-79. DOI:https://doi.org/10.1111/rda.14030.
62. Li J, Tian Y, Guo S, et al. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. PLoS One. 2018;13(1):e0191469. DOI:https://doi.org/10.1371/journal.pone.0191469.
63. Niżański W, Levy X, Ochota M, et al. Pharmacological treatment for common prostatic conditions in dogs – benign prostatic hyperplasia and prostatitis: an update. Reproduction in Domestic Animals. 2014;49(S2):8-15. DOI:https://doi.org/10.1111/rda.12297.
64. Limmanont C, Phavaphutanon J, Sirinarumitr K. Effect of finasteride and deslorelin treatment on clinical signs, prostatic volume and semen quality in dogs with benign prostatic hypertrophy: a clinical trial. Kasetsart J Nat Sci. 2012;46:724-735.
65. Villar A, Silva-Fuentes F, Mulà A, et al. Anti-inflammatory potential of Pygeum africanum bark extract: an in vitro study of cytokine release by lipopolysaccharide-stimulated human peripheral blood mononuclear cells. International Journal of Molecular Sciences. 2024;25(15):8298. DOI:https://doi.org/10.3390/ijms25158298.
66. Xiaocheng C, Shan H, Yuxing L, et al. Inhibition of spontaneous canine benign prostatic hyperplasia by an Urtica fissa polysaccharide fraction. Planta Med. 2015;81(1):10-14. DOI:https://doi.org/10.1055/s-0034-1383364.
67. Kaji K, Motegi T, Yonezawa T, et al. Anti-tumour effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines. Open Veterinary Journal. 2024;14(5):1259-1268. DOI:https://doi.org/10.5455/OVJ.2024.v14.i5.21.
68. Golchin-Rad K, Mogheiseh A, Nazifi S, et al. Changes in specific serum biomarkers during the induction of prostatic hyperplasia in dogs. BMC Veterinary Research. 2019;15(1):440. DOI:https://doi.org/10.1186/s12917-019-2201-5.
69. Pagano E, Laudato M, Griffo M, et al. Phytotherapy of benign prostatic hyperplasia: a mini-review. Phytotherapy Research. 2014;28(7):949-955. DOI:https://doi.org/10.1002/ptr.5084.
70. Derakhshandeh N, Mogheiseh A, Nazifi S. Diagnosis and Treatment of Benign Prostatic Hyperplasia in Dogs: New Approaches. Vet Med Int. 2025 22;2025:4153172. DOI:https://doi.org/10.1155/vmi/4153172.
71. Ruetten H, Wehber M, Murphy M, et al. A retrospective review of canine benign prostatic hyperplasia with and without prostatitis. Clinical Theriogenology. 2021;13(4):360-366.
72. Posastiuc FP, Constantin NT, Domain G, et al. A systematic review of medical treatments for benign prostatic hyperplasia in dogs: evaluating strategies for reproductive function preservation. Veterinary Sciences. 2025;12(1):70. DOI:https://doi.org/10.3390/vetsci12010070.
73. Romagnoli S, Diana A, Ferré-Dolcet L, et al. Chronic use of deslorelin in dogs: six cases (2005–2022). Animals (Basel). 2023;13(2):265. DOI:https://doi.org/10.3390/ani13020265.
